Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

(marketscreener.com) SAN DIEGO, Oct. 05, 2022 -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell product platform...https://www.marketscreener.com/quote/stock/FATE-THERAPEUTICS-INC-14297698/news/Fate-Therapeutics-to-Present-Clinical-and-Preclinical-Data-for-iPSC-Product-Platform-at-the-Society-41932857/?utm_medium=RSS&utm_content=20221005